#ASH17: Seat­tle Ge­net­ics CEO Clay Sie­gall has an an­swer for the skep­tics doubt­ing Ad­cetris da­ta for Hodgkin lym­phoma

Seat­tle Ge­net­ics $SGEN CEO Clay Sie­gall ran in­to a wall of skep­ti­cism last sum­mer when he rolled out pos­i­tive da­ta from their Phase III study of a new cock­tail for front­line Hodgkin lym­phoma. Drop­ping the tox­ic bleomycin from the stan­dard chemo com­bo used to treat the dis­ease, re­searchers for the biotech — part­nered with Take­da — had come up with a lean but sig­nif­i­cant 5-point PFS ad­van­tage for the com­pa­ny’s flag­ship ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.